Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Exclusion Criteria

• •1. Infection with HIV and active viral replication. Patients with an undetectable viral load on Anti-retroviral Therapy (ART) can be considered for participation on this protocol.
• •2. Infection with hepatitis B and active viral replication.
• •3. Infection with hepatitis C and active viral replication.
• •4. Patients currently being treated for bacterial, fungal or viral infection.
• •5. Documented myocardial infarction within 6 months of study participation and/or symptomatic coronary artery or valvular disease or uncontrolled arrhythmia.
• •6. Investigational drug use within 30 days before effusion collection.
• •7. Cytotoxic anti-cancer or radiation therapy administration within 2 weeks of effusion collection. The exclusion does not apply to patients receiving monoclonal antibody therapy targeting immune checkpoint molecules.
• •8. Corticosteroid therapy \> 10 mg of prednisone (biological equivalent) daily within 2 weeks before effusion collection.
• •9. Immunosuppressive therapy that cannot be stopped for 4 weeks prior to effusion collection as deemed by the prescribing physician.
• •10. Laboratory abnormalities that indicate clinically significant hematological, hepatobiliary, or renal disease:
• •AST/SGOT \> 2.0 times the upper limit of normal ALT/SGPT \> 2.0 times the upper limit of normal Total bilirubin \> 2.0 times the upper limit of normal, unless patient has Gilbert Syndrome (\>3.0 times the upper limit of normal) Hemoglobin \< 8 gm/dL or dependent upon transfusion to maintain ≥ 8 gm/dL White blood cell count \< 2,000/mm3 Platelet count \< 100,000/mm3 or dependent upon transfusion to maintain ≥ 100,000 mm3 Creatinine \> 2.0 times the upper limit of normal or calculated creatinine clearance ≤ 40 mL/min.
• •11. Pregnant or lactating females.
• •12. Prior solid organ transplantation
• •13. Patients who, in the opinion of the Investigator, will be non-compliant with study schedules or procedures.
• •14. Patients who belong to a vulnerable population such as the homeless, the developmentally disabled and prisoners or have any condition that impairs their ability to provide informed consent or comply with study schedules or procedures.
• •15. Patients with documented anaphylaxis as a result of penicillin allergy.